ERROR! No headcode.htm file found.

School of Medicine


Showing 11-20 of 469 Results

  • Katrin Andreasson

    Katrin Andreasson

    Professor of Neurology

    Current Research and Scholarly Interests Our research focuses on understanding how immune responses initiate and accelerate synaptic and neuronal injury in age-related neurodegeneration, including models of Alzheimer's disease and Parkinson's disease. We also focus on the role of immune responses in aggravating brain injury in models of stroke. Our goal is the identification of critical immune pathways that function in neurologic disorders and that can be targeted to elicit disease modifying effects.

  • Timothy Angelotti MD, PhD

    Timothy Angelotti MD, PhD

    Associate Professor of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)

    Current Research and Scholarly Interests My research efforts are focused on investigating the pharmacological and physiological interface of the autonomic nervous system with effector organs. Utilizing molecular, cellular, and electrophysiological techniques, we are examining alpha2 adrenergic receptor function in cultured sympathetic neurons. Future research aims will be directed toward understanding neurotransmitter release in general.

  • Martin S. Angst

    Martin S. Angst

    Professor of Anesthesiology, Perioperative and Pain Medicine

    Current Research and Scholarly Interests Our laboratory's current transformative research efforts focus on studying immune health in the context of surgery and anesthesia.

  • Justin P. Annes M.D., Ph.D.

    Justin P. Annes M.D., Ph.D.

    Associate Professor of Medicine (Endocrinology)

    Current Research and Scholarly Interests The ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders

    DIABETES
    The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.

    (1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual?s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.

    (2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.

    HEREDIATY PARAGAGLIOMA SYNDROME
    The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.

    As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.

  • Eric Appel

    Eric Appel

    Assistant Professor of Material Science and Engineering, by courtesy, of Pediatrics (Endocrinology) and Center Fellow, by courtesy, at the Woods Institute for the Environment

    Current Research and Scholarly Interests The underlying theme of the Appel Lab at Stanford University integrates concepts and approaches from supramolecular chemistry, natural/synthetic materials, and biology. We aim to develop supramolecular biomaterials that exploit a diverse design toolbox and take advantage of the beautiful synergism between physical properties, aesthetics, and low energy consumption typical of natural systems. Our vision is to use these materials to solve fundamental biological questions and to engineer advanced healthcare solutions.

  • Amin Arbabian

    Amin Arbabian

    Associate Professor of Electrical Engineering

    Current Research and Scholarly Interests My group's research covers RF circuits and system design for (1) biomedical, (2) sensing, and (3) Internet of Things (IoT) applications.

  • Shipra Arya

    Shipra Arya

    Associate Professor of Surgery (Vascular Surgery)

    Bio Shipra Arya, MD SM FACS is an Associate Professor of Surgery at the Stanford University School of Medicine and section chief of vascular surgery at VA Palo Alto Healthcare System. She has a Master?s degree in epidemiology from the Harvard School of Public Health with focus on research methodology and cardiovascular epidemiology. She completed her General Surgery Residency at Creighton University Medical Center followed by a Vascular Surgery Fellowship at University of Michigan. She has been funded by American Heart Association (AHA), NIH/NIA GEMSSTAR grant, VA Palo Alto Center for Innovation and Implementation (Ci2i) and is currently funded by VA HSR&D. The accumulated evidence from her research all points to the fact that frailty is a versatile tool that can be utilized to guide surgical decision making, inform patient consent and design quality improvement initiatives at the patient and hospital level. The field of frailty research in surgical population is still relatively nascent and her current work focuses on streamlining frailty evaluation, and implementation of patient and system level interventions to improve surgical outcomes and enhance patient centered care.

  • Euan A. Ashley

    Euan A. Ashley

    Associate Dean, School of Medicine, Roger W. and Joelle G. Burnell Professor of Genomics and Precision Health, Professor of Medicine (Cardiovascular Medicine), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology

    Current Research and Scholarly Interests The Ashley lab is focused on precision medicine. We develop methods for the interpretation of whole genome sequencing data to improve the diagnosis of genetic disease and to personalize the practice of medicine. At the wet bench, we take advantage of cell systems, transgenic models and microsurgical models of disease to prove causality in biological pathways and find targets for therapeutic development.

  • Themistocles (Tim) Assimes

    Themistocles (Tim) Assimes

    Associate Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health

    Current Research and Scholarly Interests Genetic Epidemiology, Genetic Determinants of Complex Traits related to Cardiovasular Medicine, Coronary Artery Disease related pathway analyses and integrative genomics, Mendelian randomization studies, risk prediction for major adverse cardiovascular events, cardiovascular medicine related pharmacogenomics, ethnic differences in the determinants of Insulin Mediated Glucose Uptake, pharmacoepidemiology of cardiovascular drugs & outcomes

Stanford Medicine Resources: